Cantor Fitzgerald’s Soleno Therapeutics SLNO Stock Holding History

Cantor Fitzgerald’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$1M	–	359
2026 Q1	$1M	Buy	+30,000	New	+$1.18M	0.01%	177
2025 Q2	–	Sell	-7,850	Closed	-$561K	–	525
2025 Q1	$561K	Buy	7,850 +3,000	+62%	+$146K	0.01%	145
2024 Q4	$213K	Buy	+4,850	New	+$251K	﹤0.01%	181

Cantor Fitzgerald's SLNO Position: Q2 2026 in Review

Cantor Fitzgerald sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 30,000 shares — an estimated $1M sold.

Cantor Fitzgerald first reported a position in SLNO in Q4 2024 and held it in 3 quarters. The position peaked at $1M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Cantor Fitzgerald reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Cantor Fitzgerald sold 30,000 Soleno Therapeutics shares in Q2 2026, an estimated $1M.
Cantor Fitzgerald first reported a position in Soleno Therapeutics in Q4 2024 and held it in 3 quarters.
Cantor Fitzgerald's Soleno Therapeutics position peaked at $1M in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.